Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
19/11/2024 01:42
Nov 19 (Reuters) - Resonance Health Ltd RHT.AX :
* RESONANCE CONTRACTED FOR CLINICAL DRUG TRIAL WORTH $13.775
MILLION
* UNIT WILL SERVE AS CRO AND LOCAL (AUSTRALIAN) SPONSOR FOR
CUSTOMER AND WILL ENGAGE AND MAKE PAYMENT TO INSTITUTIONS,
OTHERS
* ALL FIGURES IN AUD
Further company coverage: RHT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resonance Health
See all newsAustralia's Resonance Health jumps on FY26 forecast hike
Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
Brief: Resonance Health Says Martin Blake Retires As Chair
Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
Brief: Resonance Seeks Trading Halt Pending Announcement On Execution Of Contract For Services For Clinical Trial By Pharma Co